Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis

Maxine S. Eikani, Melodee Nugent, Arash Poursina, Pippa Simpson and Hara Levy

Abstract

Background: Nontuberculous mycobacteria (NTM) infections in patients with cystic fibrosis (CF) is increasing globally. However, the related epidemiology, comorbidities, and clinical impact of NTM infection remains unclear in the progress of CF lung disease and patient survival.

Methods: We performed a retrospective, case-control, cohort study (10 years), comparing NTM culture-positive CF patients (N = 28) to matched controls (N = 26). NTM positive patients were divided into two groups of slow-growing (N = 17) and rapid-growing NTM (N = 8). Three patients were positive for both slow and rapid NTM. For independent group comparisons, a non-parametric Mann-Whitney test (Kruskal-Wallis test for more than two groups) was used to compare the continuous variables, and a Fisher’s exact test was used for the categorical variables. Paired comparisons were performed using a Wilcoxon signed-rank test.

Results: The prevalence of NTM isolation was 8%. The age at CF diagnosis was significantly lower in the slow-growing NTM group compared to the rapidly growing NTM group (P = 0.04). The median percent predicted forced expiratory flow of 25% – 75% (FEF25–75) was significantly higher before NTM acquisition in slow-growing (P = 0.013) and rapidly growing NTM group (P = 0.028). The slow-growing NTM group received significantly more penicillin/beta lactamase (P = 0.010) and rifampin (P = 0.042) following isolation. Macrolide use was significantly higher after isolation in both the slow-growing NTM (P = 0.018) and rapidly growing NTM groups (P = 0.042).

Conclusions: An earlier CF diagnosis was associated with a higher isolation of slow-growing NTM and greater antimicrobial use after infection. NTM acquisition is associated with a worsening of FEF25–75. Thus, both the early diagnosis and treatment of an NTM infection in patients with CF may positively impact lung function.

Keywords: Cystic fibrosis, Nontuberculous mycobacteria, Infectious disease, Pulmonary function test, Forced expiratory volume

Background

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disease of Caucasians in the United States [1]. Improvement in the life expectancy of patients with CF is complicated by potential infection with highly resistant bacterial strains [1, 2], newly recognized virulent pathogens, and organisms, such as nontuberculous mycobacteria (NTM), which have an undetermined significance of infection associated with different subspecies [2–5]. NTM are a group of heterogeneous environmental organisms found in the soil and water throughout the world; these bacteria have historically been broadly classified into “slow” and “rapid” growers [6]. In addition, NTM may be associated with sample contamination and a spectrum of conditions...
ranging from asymptomatic infection to severe symptomatic disease [6]. Moreover, the estimated prevalence of NTM infection in patients with CF appears to be increasing (from 1.3% in 1984 to 32.7% in more recent studies) [3–8]. This increase in prevalence could be due to improvement in CF patient survival, more accurate laboratory detection techniques, and heightened clinician awareness of NTM-related lung disease [4]. Although the recognition and diagnosis of NTM-related lung diseases seems to have improved, likely due to increased awareness, consistent testing and reliable and effective treatment of NTM, especially in patients with CF, remains problematic.

NTM species diversity within CF patient populations appears to vary with geography [6, 7]. The pulmonary NTM pathogens that are most commonly isolated from CF patients in North America include the Mycobacterium avium complex (MAC), consisting of slow-growing bacteria, and the M. abscessus complex (MABSC), consisting of rapid growers [7, 9]. In contrast, MABSC is isolated from CF patients more frequently than MAC in Western Europe and Israel [7, 10–16].

Attempts to identify risk factors that can be used to predict the development of NTM infection in CF patients have not yielded consistent results. In several studies, NTM-positive CF individuals appear to be older than their NTM culture-negative counterparts [4, 7, 14, 15, 17]. Moreover, respiratory infection with MAC seems to have only a small effect on the health of CF patients [16]. In contrast, MABSC-positive patients frequently exhibit severe and occasionally fatal, lung disease [10, 18, 19]. Lung function, as assessed by percent of predicted forced expiratory volume in 1 second (FEV1), has been reported to have variable associations with NTM infection [4, 7, 10, 14, 17, 20]. In addition, the role of coexisting microbial pathogens and drug exposure remain poorly understood in the development of NTM infection. For example, Aspergillus fumigatus seems to be more prevalent in certain NTM-positive patients [8, 14, 17, 21, 22].

Treatment for NTM can be a lengthy and arduous process that is complicated by significant adverse effects [23]. Thus, a timely and accurate diagnosis of progressive NTM disease followed by appropriate management is likely to positively impact the long-term mortality and morbidity associated with CF and its treatment [7]. To meet these goals, this study sought to: 1) describe the prevalence of NTM in a large urban tertiary care university hospital and CF center; 2) characterize epidemiological factors (e.g., age, genotype, pulmonary function, co-infections, and CF comorbidities) associated with the acquisition of NTM and specific complexes; and 3) monitor the changes in antimicrobial treatment and patient pulmonary function following NTM infection.

Methods

Study patients

This retrospective, case-control, cohort study matched NTM culture-negative CF patients to culture-positive patients with CF based on genotype, age, and gender at the Children’s Hospital of Wisconsin Cystic Fibrosis Center (CHW, Milwaukee, WI). This study was approved by the Children’s Hospital of Wisconsin (CHW) Institutional Review Board (518358–8). Patients or their guardians provided informed written consent to access de-identified records from the CF Foundation registry and CHW to be used for research purposes. Clinical and research databases were queried to identify all patients diagnosed with CF based on the accepted criteria [24] who received standard care that included a minimum of quarterly visits to the CHW from December 2003 to December 2013, as well as a sample for sputum/bronchoalveolar lavage-based microbiological culture.

We included patients with an established diagnosis of CF and at least one positive NTM culture from a sputum and/or bronchoalveolar lavage sample. The exclusion criteria were defined as no history of CF and patients with CF whose acid fast bacteria (AFB) cultures were positive prior to the study period [16]. We initially identified patients with positive NTM cultures by querying the CHW Microbiology Lab database. All available patient records were reviewed to confirm the dates and details of the positive cultures. The medical records of patients meeting the inclusion criteria (N = 30) were reviewed from 1 year before the positive NTM culture until 1 year after the last positive culture or the end of the study period. Patients with positive NTM cultures were divided solely based on the isolated NTM species (slow growing and rapid growing). Acute, chronic, or transient NTM infection was not identified. All data were obtained from the patients’ medical records and the CF Foundation data registry.

For comparison purposes, one NTM culture-negative patient was matched to each NTM culture-positive patient based on CF mutation (by class) [25], age, and gender. Due to the limited number of culture-negative patients, four culture-negative patients were repeatedly matched to culture-positive patients. The timeline of the recorded data for each culture-negative patient was similar to the matched culture-positive patient.

Data collection

Demographic, clinical, and laboratory data for all eligible patients were collected from the CF Foundation registry and CHW medical records. These data included age, age at CF diagnosis, gender, race, method of CF diagnosis, CF genotype, sweat-chloride levels, pancreatic function (fecal elastase < 200 μg/g indicating pancreatic insufficiency) [26], weight, height, body mass index, FEV1,
forced expiratory flow at 25% − 75% predicted of the pulmonary volume (FEF25–75), baseline bacterial colonization, history of allergic bronchopulmonary aspergillosis (ABPA) [27], history of diabetes (type 1, type 2, or CF-related) [28], chronic medication use (macrolide, systemic steroid, inhaled steroid, inhaled antimicrobial, and inhaled hypertonic saline), serum IgE levels, serum vitamin levels (A, E, and D), NTM species identified from culture, whether the patient met the American Thoracic Society/Infectious Diseases Society of America criteria for an NTM infection [6], length and method of treatment for NTM (if any), and associated imaging changes (chest x-ray and computed tomography).

Methods of CF diagnosis were determined from the CF Foundation data registry; these methods included newborn screening and evaluation of concomitant symptoms (e.g., meconium ileus, family history of CF, recurrent sinopulmonary infections, failure to thrive, greasy or bulky stools, nasal polyps, and other signs) [24]. Patient medical records were reviewed for a history of type 1, type 2, and CF-related diabetes. CF-related diabetes was defined as oral glucose tolerance ≥200 mg/dL (≥11.1 mmol/L) and/or fasting plasma glucose levels ≥126 mg/dL (≥7.0 mmol/L) [29]. The diagnosis of ABPA was based on the presence of clinical symptoms, recent changes in chest imaging, serum total IgE levels > 1000 IU/mL (> 2400 ng/mL), immediate cutaneous reactivity to Aspergillus or in vitro presence of serum IgE and IgG antibodies to A. fumigatus [6]. FEV1 and FEF25–75 % predicted were expressed as the percent of predicted using the reference equations of Hankinson et al. [10]. Mycobacterial cultures were performed by the CHW Microbiology Lab using standard protocols to enhance the recovery of pathogens from the respiratory secretions of CF patients [7].

Data management

The study data were collected and managed using Research Electronic Data Capture (REDCap) tools hosted at Medical College of Wisconsin. This system is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. Drop-down menus and range checks were incorporated for quality control.

Statistical analysis

SPSS version 22 (IBM Software, Chicago, IL, USA) was used to analyze the data. For independent group comparisons, a non-parametric Mann-Whitney test (Kruskal-Wallis test for more than two groups) was used to compare the continuous variables, and a Fisher’s exact test was used for the categorical variables. Paired comparisons were performed using a Wilcoxon signed-rank test. Percentage estimates are reported with their respective 95% confidence intervals (CI) and continuous data with the median and range. P-values < 0.05 were considered significant.

Results

Of the 360 patients with CF who received care at CHW during the study period, 30 (8%) were identified as having had at least one positive NTM culture from a sputum sample or bronchoalveolar lavage (95% CI: 5.7–11.7). Two patients were excluded from subsequent analysis because their sputum positivity predated the study period. All patients with CF who were included in the study (N = 28) visited the CHW CF care center at least four times per year. The total number of reviewed visits per patient ranged from 4 to 42 (median: 12; Fig. 1).

Of the 17 patients infected with slow-growing NTM, 15 (88% [95% CI: 63–99]) harbored MAC and two (12% [95% CI: 2–36]) harbored M. gordonae. Eight patients were infected with rapidly growing mycobacteria: six patients with MABSC (75%) and two patients (25%) with M. fortuitum. The median age at the time of the first NTM isolation was 16.4 years; patients infected
with slow-growing NTM ranged in age from 6.4 to 41.6 years and patients infected with rapidly growing NTM ranged in age from 3.1 to 21.5 years (P = 0.44).

Although newborn screening for CF began in 1994 in Wisconsin and was implemented nationwide in 2010 [24, 30], variability remains for the age at diagnosis and missed cases of CF [30]. The age of CF diagnosis for those with slow-growing NTM was significantly lower (median: 1.2 months [range: 0.1 – 2.8 months]) compared to those with rapidly growing NTM (median: 4.5 months [range 1.5 – 84.3 months]) and NTM-negative patients (2.4 months [range: < 1 – 164 months]; P = 0.04; Table 1). The patients’ age at CF diagnosis significantly differed between those infected with rapidly growing NTM and the NTM-negative patients (P = 0.013).

Patient demographics, including gender, race, and method of CF diagnosis, did not significantly differ based on infection status (Table 1). The most common CF genotype in both groups was F508del homozygous (59% of patients infected with slow-growing NTM and 50% of patients infected with rapidly growing NTM; Table 1). The sweat-chloride levels significantly differed between those with slow-growing NTM (median: 101 mmol/L [range: 74 – 121 mmol/L]) and rapidly growing NTM (median: 105 mmol/L [range: 100 – 142 mmol/L]) and NTM-negative patients (median: 109 mmol/L [range: 90 – 137 mmol/L]; P = 0.026), as well as between the patients infected with slow-growing NTM and the NTM-negative patients (P = 0.009; Table 1). All patients in the slow- and rapidly growing NTM groups exhibited pancreatic insufficiency; only one patient in the NTM-negative group displayed pancreatic sufficiency (Table 1). There was no significant difference between the three groups regarding a history of diabetes or FEV1 before or after NTM acquisition (Table 1).

The FEF25–75 was evaluated to assess the potential effect of an NTM infection on the smaller airways. The median FEF25–75 (expressed as the percent predicted) before the acquisition of slow-growing NTM was 79 (range: 24 – 124) and after acquisition was 68 (range: 13 – 110; P = 0.013; Table 2). This difference was also significant for patients infected with rapidly growing NTM, who had a median FEF25–75% predicted of 64 (range: 42 – 123) before NTM acquisition and 51 (range: 24 – 103) after acquisition (P = 0.028; Table 2).

Of the culture-positive patients, 13 (52%) had one positive culture and 15 (48%) had multiple positive cultures. CF patients with more than four positive cultures for rapidly growing NTM had a larger range for the median FEF25–75 (Fig. 2, Table 3), suggesting that the patients with more positive cultures had a lower FEF25–75 (Fig. 2; Table 3). The most common bacterial colonization in both infection groups was Pseudomonas aeruginosa, followed by Staphylococcus aureus, Stenotrophomonas maltophilia, and Acinetobacter baumannii (Table 4).

Mycobacterial lung infection was assessed based on the American Thoracic Society criteria [9]. A total of 11 out of 16 (69%) patients infected with slow-growing NTM and all 6 (100%) patients infected with rapidly growing NTM exhibited clinical symptoms of an increased cough, sputum production, or shortness of breath at rest and upon exertion at the time of the positive NTM culture (Table 4). Seven patients (44%) infected with slow-growing NTM and three patients (50%) infected with rapidly growing NTM displayed image changes (e.g., new infiltrates, new bronchiectasis, consolidation, and nodules) on chest x-ray or computed tomography (Table 4). There were 11 patients infected with slow-growing NTM (69%) and 4 patients infected with rapidly growing NTM (67%) who had two positive sputum cultures or 1 positive bronchoalveolar lavage (Table 4). Only two patients infected with slow-growing NTM (25%) received treatment for NTM infection (Table 4).

Significantly more patients infected with slow-growing NTM received penicillin/beta-lactamase inhibitors following NTM acquisition (median: 4 [range: 0 – 9]) than those prior to NTM acquisition (median: 0.5 [range: 0 – 3]; P = 0.010). These patients also received rifampin following NTM acquisition (median: 5; [range: 2 – 7]); P = 0.042; Table 5). Macrolide use was significantly more frequent after NTM acquisition than before acquisition in both the slow-growing (P = 0.018) and rapidly growing NTM groups (P = 0.042; Table 5).

There were three culture-positive patients infected with both MAC and MABSC at different times during the study period. All three patients were Caucasian and one was male; they were aged 7, 15, and 18 years at the time of the positive NTM culture. Two patients were homozygous for F508del. One was colonized with S. aureus, and the other two were colonized with S. aureus and P. aeruginosa. The median FEV1 was 86, 104, and 98 before NTM acquisition, and 75, 74, and 100 after NTM acquisition. The median FEF25–75% predicted was 72, 91, and 86 before NTM acquisition and 54, 49, and 87 following NTM acquisition.

Discussion

There has been an increase in the isolation of NTM bacteria from the respiratory secretions of CF patients [2–6]. Although NTM infection was present in 8.3% of our CF patients during the study period, this value is relatively similar to previous studies [2, 5, 8–11]; however, this may not reflect the true prevalence. Many of our CF patients
|                                | Patients with Slow-growing NTM #1 (N = 17) | Patients with Rapidly Growing NTM #2 (N = 8) | NTM-negative Patients #3 (N = 26) | P-values          |
|--------------------------------|-------------------------------------------|---------------------------------------------|---------------------------------|------------------|
|                                | N  | N (%) or median (range) | N  | N (%) or median (range) | N  | N (%) or median (range) | Overall | 1 vs 2 | 1 vs 3 | 2 vs 3 |
| Age at first positive NTM culture, years | 17 | 16.4 (6.4–41.6)      | 8  | 16.4 (3.1–21.5)           | –   | –                            | 0.44a    | 0.44a |
| Gender                         | 17 |                           | 8  |                           | 26  |                           | 0.93     | 0.99  | 0.75  | 0.99  |
| Male                           | 9  | (53)                      | 5  | (63)                        | 16  | (62)                        |          |       |       |       |
| Female                         | 8  | (47)                      | 3  | (37)                        | 10  | (38)                        |          |       |       |       |
| Age at CF diagnosis in months  | 11 | 1.2 (0.1–2.8)            | 5  | 4.5 (1.5–84.3)             | 22  | 2.4 (< 1–164.4)             | 0.046    | 0.013 | 0.053 | 0.52  |
| Race                           | 15 |                           | 8  |                           | 26  |                           | 0.37     | 0.35  | 0.29  | 0.99  |
| Caucasian                      | 15 | (100)                     | 7  | (88)                        | 23  | (88)                        |          |       |       |       |
| Black/Hispanic                 | –  |                           | 1  | (12)                        | 3   | (12)                        |          |       |       |       |
| CF diagnosis method b          | 12 |                           | 5  |                           | 24  |                           |          |       |       |       |
| Newborn screening              | 8  | (67)                      | 1  | (20)                        | 10  | (42)                        | 0.24     | 0.18  | 0.75  | 0.23  |
| Concomitant symptoms           |    |                           |    |                             |     |                             |          |       |       |       |
| Meconium                       | 3  | (25)                      | –  |                             | 5   | (21)                        | 0.51     | 0.53  | 0.99  | 0.31  |
| Chronic cough                  | 1  | (8)                       | –  |                             | –   |                             | 0.49     | 0.99  | 0.40  | –     |
| Recurrent respiratory infection| 2  | (17)                      | 4  | (80)                        | 10  | (42)                        | 0.08     | 0.06  | 0.09  | 0.69  |
| Failure to thrive              | 3  | (25)                      | 4  | (80)                        | 8   | (33)                        | 0.25     | 0.16  | 0.48  | 0.41  |
| Frequent greasy or bulky stools| 1  | (8)                       | –  |                             | –   |                             | 0.49     | 0.99  | 0.40  | –     |
| Nasal polyps                   | –  |                           | –  |                             | 1   | (4)                         | 0.92     | –     | 0.99  | 0.99  |
| Other                          | 1  | (8)                       | 2  | (40)                        | 4   | (17)                        | 0.41     | 0.23  | 0.63  | 0.61  |
| p.508del mutation status       | 17 |                           | 8  |                             | 26  |                             | 0.44     | 0.46  | 0.25  | 0.84  |
| 2 copies                       | 10 | (59)                      | 4  | (50)                        | 17  | (65)                        |          |       |       |       |
| 1 copy                         | 7  | (41)                      | 3  | (38)                        | 6   | (23)                        |          |       |       |       |
| 0 copies                       | –  |                           | 1  | (12)                        | 3   | (12)                        |          |       |       |       |
| Sweat-chloride level at diagnosis, mmol/L. | 13 | 101 (74–121) | 5  | 105 (100–142) | 22  | 109 (90–137) | 0.026d | 0.095 | 0.009 | 0.99  |
| Pancreatic insufficiency       | 17 |                           | 8  |                             | 26  |                             | 0.92     | –     | 0.99  | 0.99  |
| No                             | –  |                           | –  |                             | 1   | (4)                         |          |       |       |       |
| Yes                            | 17 | (100)                     | 8  | (100)                       | 25  | (96)                        |          |       |       |       |
| Diabetes diagnosis             | 17 |                           | 8  |                             | 26  |                             | 0.67     | 0.99  | 0.67  | 0.57  |
| No                             | 14 | (82)                      | 6  | (75)                        | 23  | (88)                        |          |       |       |       |
| Yes                            | 3  | (18)                      | 2  | (25)                        | 3   | (12)                        |          |       |       |       |
| FEV1 percent predicted         |    |                           |    |                             |     |                             |          |       |       |       |
|                                      | Patients with Slow-growing NTM #1 (N = 17) | Patients with Rapidly Growing NTM #2 (N = 8) | NTM-negative Patients #3 (N = 26) | P-values |
|--------------------------------------|------------------------------------------|---------------------------------------------|----------------------------------|----------|
|                                      | N (%) or median (range)                  | N (%) or median (range)                     | N (%) or median (range)          | Overall 1 vs 2 1 vs 3 2 vs 3 |
| **Before NTM acquisition**           |                                          |                                              |                                  |          |
| N                                    | 17                                       | 7                                            | –                                | 0.80     |
| N (%) or median (range)              | 92 (53–115)                              | 84 (71–102)                                  | –                                | 0.80     |
| **After NTM acquisition**            |                                          |                                              |                                  |          |
| N                                    | 17                                       | 8                                            | –                                | 0.23     |
| N (%) or median (range)              | 91 (36–110)                              | 80 (48–91)                                   | –                                | 0.23     |
| **FEF25–75% predicted**              |                                          |                                              |                                  |          |
| Before NTM acquisition                |                                          |                                              |                                  |          |
| N                                    | 17                                       | 7                                            | –                                | 0.80     |
| N (%) or median (range)              | 79 (24–124)                              | 64 (42–123)                                  | –                                | 0.80     |
| **After NTM acquisition**            |                                          |                                              |                                  |          |
| N                                    | 17                                       | 8                                            | –                                | 0.59     |
| N (%) or median (range)              | 68 (13–110)                              | 51 (24–103)                                  | –                                | 0.59     |
| **Organism type**                    |                                          |                                              |                                  |          |
| MAC                                  | 15 (88)                                  | –                                            | –                                | ≤0.001   |
| M. fortuitum                         | –                                        | 2 (25)                                       | –                                | ≤0.001   |
| M. abscessus                         | –                                        | 6 (75)                                       | –                                |          |
| M. gordonae                          | 2 (12)                                   | –                                            | –                                |          |
| Number of positive NTM cultures      | 17                                       | 8                                            | 2.5 (1–7)                       | 0.18     |
|                                      | 1 (1–3)                                  | 2.5 (1–7)                                    | –                                | 0.18     |

*Significant difference between patients infected with rapidly growing bacteria and NTM-negative patients (P = 0.013)

bMore than one method of diagnosis may have been used

cSignificant difference between patients infected with slow-growing bacteria and NTM-negative patients (P = 0.009)
rarely underwent mycobacterial analysis and some never underwent any mycobacterial testing. This omission may be due to difficulties with the collection of adequate and appropriate specimens in younger patients, the indeterminate significance of these organisms in the CF population, and a lack of awareness and consistency among providers in obtaining NTM cultures as part of routine CF care [7].

More than 160 species of NTM have been characterized to date; of which a select few are associated with clinical disease in humans. Each member of this heterogeneous group of organisms has its own microbiological and clinical significance, with equally diverse treatment and resistance profiles [6]. The most common NTM

| Table 2 | Comparison of patients infected with slow-growing or rapidly growing NTM |
|---------|--------------------------------------------------|
| Patients with Slow-growing NTM (N = 17) | Patients with Rapidly Growing NTM (N = 8) |
| N | Median (range) | P-value | N | Median (range) | P-value |
|---|----------------|---------|---|----------------|---------|
| Body mass index in kg/m² | 16 | 19.8 (15.0–23.9) | 0.35 | 19.3 (14.7–21.7) | 0.069 |
| Before NTM infection | 19.6 (15.2–25.9) | | | 20.4 (15.1–21.7) | |
| After NTM infection | 17 | 92 (53–115) | 0.11 | 84 (71–102) | 0.23 |
| Before NTM infection | 91 (36–110) | | | 82 (48–91) | |
| After NTM infection | FEF25–75% predicted | 17 | 79 (24–124) | 0.013 | 7 | 0.028 |
| Before NTM infection | 68 (13–110) | | | 64 (42–123) | |
| After NTM infection | IgE in kU/L | 16 | 34 (8–2165) | 0.55 | 7 | 0.61 |
| Before NTM infection | 34 (9–1340) | | | 95 (18–419) | |
| After NTM infection | Vitamin A in μg/dL | 11 | 39 (19–83) | 0.19 | 5 | 0.23 |
| Before NTM infection | 45 (25–79) | | | 33 (15–45) | |
| After NTM infection | Vitamin E in mg/L | 9 | 8 (2–13) | 0.37 | 5 | 0.50 |
| Before NTM infection | 9 (2–14) | | | 7 (6–11) | |
| After NTM infection | **Table 3** Median difference in FEF25–75 before and after NTM acquisition vs. the number of positive cultures |
| 1 | 2 | 3 | 4 |
|---|---|---|---|
| Slow growers | N | 10 | 4 | 3 | 0 |
| Median | 6.3 | 6.0 | 10.5 | – |
| Range | –11.5–18.5 | 0.5–13.0 | 4.5–11.0 | – |
| Rapid growers | N | 3 | 1 | 1 | 2 |
| Median | 3.0 | 0 | 20 | 35.5 |
| Range | 1.0–18.0 | – | – | 20.5–50.5 |

Fig. 2 Median difference in the FEF 25–75 in CF patients with more than four positive cultures
species isolated in our study was MAC, followed by MABSC (Table 1); this observation is consistent with other reports [2, 4, 7, 9, 10, 15, 17, 31]. Catherinot et al. [16] compared CF patients infected with MAC and MABSC in France and found that MAC was more common in adult patients with mild CF, whereas MABSC more frequently infected younger patients with more severe CF [16]. Our results do not fully confirm the results of Catherinot et al., since the median age was similar between the culture-positive groups (Table 1). Historically, *M. gordonae* was classified as the most common contaminant NTM species; however, there have been reports of infection with this organism in patients with CF [6, 18].

Our analyses revealed a significant relationship between the patients’ age at CF diagnosis and infection with rapidly growing mycobacteria (Table 1). Early CF diagnosis via newborn screening and recent advances in medical care are expected to facilitate better preventive care and management of CF patients infected with NTM [28]. Delays in the initial diagnosis of CF generally lead to a late start in patient management, potentially resulting in poorer general health, malnutrition, and more advanced lung disease, all of which contribute to infection with rapidly growing mycobacteria [28, 31].

Multiple prospective and retrospective studies have yielded inconsistent results regarding the possible effects of NTM infection on the progression of CF lung disease [7, 10, 14, 17, 20]. To the best of our knowledge, the current investigation is the first single center study in the US to compare the effects of slow- and rapidly-growing NTM on the smaller airways by comparing the FEF25–75 before and after NTM acquisition in CF patients. Previous studies have suggested that FEF25–75 is a sensitive indicator of early disease in children with CF [13], which our current study further supports. Similarly, Bakker et al. [13] reported that FEF75 is a more sensitive marker of early CF lung disease than FEV1 and forced vital capacity because abnormalities in FEF75 occur at a younger age and FEF75 decreases more than other pulmonary-function parameters. In the present study, FEV1 as a measure of pulmonary function did not differ before and after NTM acquisition in either infection group; however, we did detect significantly

| Table 4 Microbiology of the patient cohort |
|-------------------------------------------|
| Patients with Slow-growing NTM (N=17) | Patients with Rapidly Growing NTM (N=8) | P-value |
| **N** | **N (%)** | **N** | **N (%)** | **N** | **N (%)** |
| **Common bacterial colonization at time of positive NTM** | | | | | |
| *P. aeruginosa* | 13 (76) | 8 (100) | 0.27 |
| Methicillin-susceptible *S. aureus* | 13 (76) | 5 (63) | 0.64 |
| Methicillin-resistant *S. aureus* | 6 (35) | 3 (38) | 0.99 |
| *S. maltophilia* | 4 (22) | 4 (50) | 0.36 |
| *Escherichia coli* | 1 (6) | – | 0.99 |
| *A. baumannii* | – | 1 (13) | 0.32 |
| None | 1 (6) | – | 0.99 |
| **History of ABPA** | | | | | |
| Before NTM infection | 17 | 8 | 0.53 |
| No | 14 (82) | 8 (100) | |
| Yes | 3 (18) | – | |
| After NTM infection | 17 | 8 | 0.64 |
| No | 13 (76) | 5 (62) | |
| Yes | 4 (24) | 3 (38) | |
| **American Thoracic Society treatment criteria** | 16 | 6 | 0.58 |
| Clinical | 11 (69) | 6 (100) | 0.27 |
| New changes on chest x-ray or computed tomography | 7 (44) | 3 (50) | 0.99 |
| Two positive sputum or bronchoalveolar lavage | 11 (69) | 4 (67) | 0.99 |
| **Received treatment for NTM** | 16 | 8 | 0.58 |
| No | 14 (88) | 6 (75) | |
| Yes | 2 (12) | 2 (25) | |

*aNontuberculous mycobacteria*  
b*Allergic bronchopulmonary aspergillosis*
lower FEF25–75 after NTM acquisition in both culture-positive patient groups (Table 2). Patients with more than four cultures positive for rapidly growing NTM were associated with the greatest change in the median FEF25–75 throughout the follow-up period (Table 3; Fig. 2). This is likely because patients with rapidly growing NTM can have more acute and severe clinical symptoms [6, 7]. Unfortunately, inadequate and inappropriate exposure of NTM to antimicrobials can also lead to the development of antibiotic resistance [32].

The increased use of macrolides following NTM acquisition (Table 5) is rarely a component of a multidrug regimen recommended for the treatment of certain mycobacterial species (e.g., M. abscessus). In addition to their antibacterial properties, macrolides (i.e., azithromycin) are most often chosen for their immunomodulatory activity to improve respiratory function and reduce the frequency of pulmonary exacerbations [21]. Screening for an NTM infection in CF patients prior to the initiation of macrolide therapy should be a universal practice. The increased use of macrolides after NTM acquisition may reflect the clinical decline of these patients, which supports the earlier observation of NTM infection has a negative impact on small airway function in patients with CF.

Table 5: Quantitative comparison of antimicrobial prescriptions before and after NTM acquisition

|                         | Patients with Slow-growing NTM \( (N = 17) \) | Patients with Rapidly Growing NTM \( (N = 8) \) |
|-------------------------|---------------------------------------------|-----------------------------------------------|
|                         | Before                                      | After                                         | Before                                      | After                                         | P-value                              |
|                         | N Median (range)                            | Median (range)                                | N Median (range)                            | Median (range)                                |                                    |
| Penicillins/Beta lactamase      | 12 0.5 (0–3)                                         | 4 (0–9)                                      | 4 1.5 (0.2)                                         | 1.5 (1.6)                                       | 0.010                                |
| Cephalosporin             | 5 2 (0–5)                                          | 1 (0–2)                                      | 2 1 (0–2)                                          | 13.5 (0–27)                                     | 0.99                                 |
| Glycopeptide \(^a\)       | –                                           | –                                            | –                                            | 1 0                                           | 2                                    |
| Carbapenems \(^a\)        | 3 0 (0–0)                                          | 2 (1–8)                                      | 2 0.5 (0–1)                                      | 5.5 (0–11)                                     | 0.018                                |
| Monobactam \(^b\)         | 2 0.5 (0–1)                                      | 0.5 (0–1)                                     | 3 0 (0–0)                                       | 2 (1–3)                                        | 0                                    |
| Aminoglycosides           | 11 1 (0–5)                                      | 3 (0–10)                                     | 5 2 (0–5)                                       | 5 (2–18)                                       | 0.11                                 |
| Macrolides                | 7 0 (0–0)                                        | 5 (1–8)                                      | 5 0 (0–2)                                       | 3 (1–17)                                       | 0.042                                |
| Lincosamides \(^c\)       | 2 0 (0–0)                                        | 1 (1–1)                                      | 1 1                                           | 0                                             | 0.32                                 |
| Oxazolidinones \(^d\)     | 1 0                                           | 1                                            | 1 0                                           | 1                                             | 0.32                                 |
| Fluoroquinolones          | 9 2 (0–4)                                        | 2 (0–4)                                      | 6 0.5 (0–2)                                    | 4.5 (0–26)                                     | 0.11                                 |
| Antifolates \(^e\)        | 8 1 (0–7)                                       | 1 (0–13)                                     | 4 1 (0–4)                                    | 2 (1–4)                                        | 0.41                                 |
| Rifamycins \(^f\)         | 5 0 (0–0)                                       | 5 (2–7)                                      | 0 –                                           | –                                             | –                                    |

\(^a\)Vancomycin
\(^b\)Aztreonam
\(^c\)Clindamycin
\(^d\)Linezolid
\(^e\)Trimethoprim/sulfonamides
\(^f\)Rifampin

Coexisting microbial pathogens have an undetermined role in the development of NTM infection. In the current study, the most common bacterial colonization in both culture-positive groups was P. aeruginosa, followed by S. aureus (Table 4). A variable prevalence of NTM isolation in patients with underlying P. aeruginosa and S. aureus colonization has been reported in multiple studies [10, 14]; however, there is some evidence of a higher prevalence of A. fumigatus colonization among NTM-positive patients [10, 14, 16], as well as an association of NTM with ABPA [22]. Despite these previous reports, we failed to detect a significant relationship between a history of ABPA and NTM acquisition.

Penicillin, beta-lactamase inhibitors, and rifampin use was higher in our patients infected with slow-growing NTM compared to the patients infected with rapidly growing NTM (Table 5). This observation may reflect a decline in patient clinical status that leads to more frequent hospitalization and antibiotic administration in inpatient and ambulatory settings. Many of the antimicrobials used to treat underlying bacterial colonization exhibit some activity against NTM species and may interfere with an accurate diagnosis of the infection and evaluation of subsequent pulmonary function [6, 7]. Unfortunately, inadequate and inappropriate exposure of NTM to antimicrobials can also lead to the development of antibiotic resistance [32].

This study has several limitations: 1) NTM screening was not routinely practiced at our center during the 10-year study period; however, it may have been
performed more often in patients who did not respond satisfactorily to conventional treatments. As a result, our data may not reflect the overall prevalence of these organisms in the study population; 2) our cohort did not have a large variety of CF gene mutation profiles. This is primarily attributed to the predominance of Caucasians in our patient population, which precluded our ability to detect a relationship between ethnicity or genotype and NTM infections; 3) retrospective studies can be limited by ascertainment bias, despite our best efforts to review every available medical record; and 4) a single, tertiary care, referral center study with small sample size may not adequately represent the entire CF population in the US; multiple variables (e.g., race, geography, and practice patterns) may influence the disease presentation and outcome.

Conclusion
This single CF center study sheds light on the negative impact of NTM infection in the smaller airways of patients with CF and reveals a significant link between age at diagnosis and NTM infection. Future prospective, multicenter studies with larger and more diverse patient populations are required to better define the impact of NTM on CF outcomes and how infections can best be detected and managed in this population. Thus, our findings indicate that increased awareness by clinicians on different NTM subtypes and more universal treatment plan for NTM infection in the CF population may positively impact patient management and outcomes.

Abbreviations
ABPA: Allergic bronchopulmonary aspergillosis; CF: Cystic fibrosis; CHW: Wisconsin cystic fibrosis center; FEF25–75: Percent predicted forced expiratory flow at 25–75%; FEV1: Forced expiratory volume in 1 s; MABSC: Mycobacterium abscessus complex; MAC: Mycobacterium avium complex; NTM: Nontuberculous mycobacteria

Acknowledgments
We acknowledge the assistance of the Cystic Fibrosis Center staff at the Children’s Hospital of Wisconsin in Milwaukee, Wisconsin, USA. We thank all of our CF patients and their families; we appreciate their involvement and support. We are grateful to Dr. Sue Kehl, the Director of the Microbiology Laboratory at Children’s Hospital of Wisconsin, for providing patient data. We also thank Laura Roth, CF Center Research Coordinator, for her assistance with data collection, as well as the staff of the Pulmonary Function Laboratory of Children’s Hospital of Wisconsin, Sheryl Stanczik, and Kirk Smikowski for further assistance in data collection. Special thanks go to Theresa Kump, the CF Research Coordinator.

Funding
This work was supported by a Children’s Hospital of Wisconsin & Health System grant to HL; Children’s Research Institute Pilot Innovative Research Grant to HL and MSE; and NIH/NHLBI Director’s New Innovator Award [1DP2 OD 00703] to HL.

Availability of data and materials
The de-identified dataset used during the current CF NTM study is available from the corresponding author upon reasonable written request.

Authors’ contributions
MSE assisted with the conception and design of the study, data collection, and data analysis and drafted the manuscript. MN and PS assisted with study design, protocol development, and data analysis and edited the manuscript. MN assisted with data analysis and edited the manuscript. AP assisted with the conception, design, and interpretation of the study and edited the manuscript. HL delineated the hypothesis, helped conceive and design the study, performed and oversaw the data analyses, and assisted in the writing of the manuscript. All authors read and approved the final manuscript for submission and publication.

Ethics approval and consent to participate
This study was approved by the Children’s Hospital of Wisconsin Institutional Review Board (S18358–8). Patients or their guardians provided written informed consent to access de-identified records from the CF Foundation registry and Children’s Hospital of Wisconsin to be used for research purposes.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Novant Health Pediatric Pulmonology, Novant Health Hemby Children’s Hospital, Charlotte, NC, USA. 2Children’s Research Institute, Children’s Hospital of Wisconsin, Milwaukee, WI, USA. 3Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, WI, USA. 4Piedmont Medical Center Infectious Disease, Piedmont Medical Center, Rock Hill, SC, USA. 5Division of Pulmonary, MedicineNorthwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital, Chicago, IL, USA. 6Department of Pediatrics, Section of Pulmonary Medicine, Human Molecular Genetics Program, Stanley Manne Children’s Research Institute, Northwestern University Feinberg School of Medicine, 225 E. Chicago Ave, Chicago, IL, USA.

Received: 21 October 2017 Accepted: 20 June 2018

Published online: 06 July 2018

References
1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2013 Annual Data Report to the Center Directors. Bethesda, 2013. Available from: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf.
2. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, et al. Nontuberculous mycobacteria: II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167(6):835–40. Epub 2002. 11.14
3. Bar-On O, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Stafler P, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros. 2015;14(1):53–62. https://doi.org/10.1016/j.jcf.2014.05.008.
4. Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med. 2013;34(1):124–34. https://doi.org/10.1055/s-0033-1333574.
5. Qvist T, Gilljam M, Jonsson B, Taylor-Robinson D, Jensen-Fangel S, Wang M, et al. And on behalf of the Scandinavian cystic fibrosis study consortium (SCFSC). Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros. 2015;14(1):46–52. https://doi.org/10.1016/j.jcf.2014.08.002.
6. Griffith DE, Akramt M, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367–416. https://doi.org/10.1164/rccm.200604-571ST.
7. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in
individuals with cystic fibrosis: executive summary. Thorax. 2016;71(1):88–90. https://doi.org/10.1136/thoraxjnl-2015-207983.
8. Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol. 2009;47(12):4124–8. https://doi.org/10.1128/JCM.01257-09.
9. Saliglieri EL, Fink AK, Knupp EA, LiPuma JJ, Oliver KN, Marshall BC, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149(2):390–400. https://doi.org/10.1378/chest.15-0676.
10. Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol. 2005;40(1):35–44. https://doi.org/10.1002/ppul.20222.
11. Seddon P, Fidler K, Raman S, Wyatt H, Ruiz G, Eksen C, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis. 2013;19(7):1128–30. https://doi.org/10.3201/eid1907.120615.
12. Valenza G, Tappe D, Turnwald D, Frosch M, Konig C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7(2):123–7. https://doi.org/10.1016/j.jcf.2007.06.006.
13. Bäkker EM, Bomboorn GJ, van der Wiel-Kooij EC, Caufield D, Rosenfeld M, Tiddens HA. Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. Pediatr Pulmonol. 2013;48(11):1081–8. https://doi.org/10.1002/ppul.22777.
14. Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L, et al. Prevalence, and antibiotic treatment of non-tuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis. 2008;14(3):378–84. https://doi.org/10.3201/eid1403.061405.
15. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, Vuillemin A, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol. 2005;43(7):3467–70. https://doi.org/10.1128/JCM.43.7.3467-3470.2005.
16. Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros. 2013;12(1):74–80. https://doi.org/10.1016/j.jcf.2012.06.009.
17. Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest. 1993;103(4):1096–9.
18. Verma N, Spencer D. Disseminated Mycobacterium gordonae infection in a child with cystic fibrosis. Pediatr Pulmonol. 2012;47(5):517–8. https://doi.org/10.1002/ppul.21574.
19. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respit Crit Care Med. 2000;161(2 Pt 1):641–5. https://doi.org/10.1164/ajrccm.161.2.9903062.
20. Radhakrishnan DK, Yau Y, Corey M, Richardson S, Chedore P, Jamieson F, et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol. 2006;44(11):1100–6. https://doi.org/10.1002/ppul.21106.
21. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2011;121(9):3554–63. https://doi.org/10.1172/JCI46095.
22. Mussaffi H, Rivlin J, Shaltt L, Ephros M, Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J. 2005;25(2):324–8. https://doi.org/10.1183/09031936.05.0058604.
23. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respit Crit Care Med. 2003;168(9):918–31. https://doi.org/10.1164/ircrm.200304-505SO.
24. Farrell PM, Rosenfeld BI, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4–S14. https://doi.org/10.1016/j.jpeds.2008.05.005.
25. Lommatzsch ST, Aris R. Genetics of cystic fibrosis. Semin Respit Crit Care Med. 2009;30(5):531–8. https://doi.org/10.1055/s-0029-1238911.
26. Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr. 2013;162(4):808–12 e1. https://doi.org/10.1016/j.jpeds.2012.10.008.
27. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation consensus conference. Clin Infect Dis. 2003;37(Suppl 3):S225–64. https://doi.org/10.1086/376525.
28. Parker-McCill K, Nugent M, Besrie R, Hoffman G, Rock M, Baker M, et al. Changing incidence of cystic fibrosis in Wisconsin, USA. Pediatr Pulmonol. 2015;50(1):1065–72. https://doi.org/10.1002/ppul.22365.
29. Moran A, Pillay K, Becker DJ, Acrerini CL. International Society for P, adolescent D. ISPAD clinical practice consensus guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2014;15(Suppl 20):65–76. https://doi.org/10.1111/pdi.12178.
30. Rock MJ, Levy H, Zaleski C, Farrell PM. Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. Pediatr Pulmonol. 2011;46(12):1166–74. https://doi.org/10.1002/ppul.21509.
31. Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010;9(2):117–23. https://doi.org/10.1016/j.jcf.2009.12.001. Epub 2010.1.13.
32. Qvist T, Plessler T, Haeby N, Katzenstein TL. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res. 2014;15:41. https://doi.org/10.1186/1465-9211-15-41.